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Abstract
Melatonin, a pineal hormone that induces sleep, has become a popular over-the-counter drug. The cellular effects of
melatonin, however, are only beginning to be studied. We have recently shown that stimulation of the mt1 melatonin receptor
induces rapid and dramatic cytoskeletal rearrangements in transformed non-neuronal cells (Witt-Enderby et al., Cell. Motil.
Cytoskel. 46 (2000) 28). These cytoskeletal changes result in the formation of structures that closely resemble neurites. In this
work, we show that the N1E-115 mouse neuroblastoma cell line rapidly responds to melatonin stimulation and forms
neurites within 24 h. We also demonstrate that these cells readily bind 2-[125I]iodomelatonin at levels consistent with what is
noted for native tissues (Bmax = 3.43 þ 1.56 fmol/mg protein; Kd = 240 pM). Western analysis shows that these cells possess
and express melatonin receptors of the mt1 subtype. Treatment with pertussis toxin eliminates neurite formation whereas
treatment with the MT2 subtype-specific activator, BMNEP, does not induce neurite formation. We have previously shown
that increases in MEK 1/2 and ERK 1/2 phosphorylation are correlated with the shape changes in transformed CHO cells.
Western analysis of the MEK/ERK signaling pathway in N1E-115 cells shows that this pathway is most likely maximally and
constitutively stimulated. This may account for the spontaneous production of neurites noted for this cell line after long
culture periods. The results of this work show that melatonin receptor stimulation in a neuronal cell type results in the
formation of neurites and that the receptors responsible for melatonin-induced neurite formation in N1E-115 cells are most
likely of the mt1 subtype. ß 2001 Elsevier Science B.V. All rights reserved.
Keywords: Melatonin; mt1 receptor; N1E-115 cell ; Neurite; Neuronal development; Signal transduction
1. Introduction
Melatonin, N-acetyl-5-methoxytryptamine, has
been shown to be an important neuronal hormone
for establishing circadian rhythms in several animal
species, including humans. In animals and humans, it
is produced and secreted into the bloodstream in
response to darkness. In clinical trials, melatonin is
an e¡ective inducer of sleep and also improves the
quality of sleep [1]. Melatonin is a small lipophilic
molecule capable of traversing the plasma membrane
[2] however, its major mechanisms of action are
mediated by membrane-bound G-protein-coupled re-
ceptors.
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Two human melatonin receptor subtypes have
been cloned [3,4], and classi¢ed by the International
Union of Pharmacology as mt1 and MT2 [5]. These
receptors are considered unique subtypes based on
their molecular structure, pharmacological responses
and chromosomal localization [4,6]. The mt1 melato-
nin receptor, believed to mediate circadian function,
is highly expressed in the suprachiasmatic nucleus of
the hypothalamus (SCN) [3], whereas the MT2 mel-
atonin receptor, which may be involved in both cir-
cadian entrainment and retinal physiology, is ex-
pressed in both the brain and retina [4,7,8].
Melatonin acts in a receptor-dependent manner [9^
11] and has also been proposed to act in a receptor-
independent manner [1,12,13]. Activation of endoge-
nous mt1 receptor expressed in the suprachiasmatic
nucleus of the hypothalamus [14] ovine pars tuberalis
cells [10] as well as in transfected CHO [15] or COS-7
cells [3] by melatonin results in a reduction of cAMP
formation via pertussis toxin sensitive and insensitive
G-proteins [10,11,15] This receptor is also capable of
stimulating the Ca2/IP3 signaling pathway [4,9^
11,16^19]. Recent work has con¢rmed that the mt1
receptor signals through two inhibitory G proteins
(GKi2 and GKi3) that attenuate adenylyl cyclase activ-
ity and one G protein (GKq=11) that increases phos-
pholipase C activity [19]. The MT2 receptor has been
shown to attenuate adenylyl cyclase activity
[4,11,19,20] and has additionally been linked with
the inhibition of guanylyl cyclase activity [21,22].
Although important advances have been made in
delineating melatonin receptor signaling, the com-
plete pathways of these receptors’ actions are far
from complete.
The means by which neurons produce axons and
dendrites has intrigued neuroscientists for over a cen-
tury. Speculations set forth in 1890 by Ramon y
Cajal [23] concerning the ‘mysterious forces’ that
cause neuronal outgrowths and connections still en-
tice scientists to this day. Proper connections be-
tween neurons and their targets are needed to estab-
lish a functional nervous system. Hormones and
neurotrophic factors have strong e¡ects on the orga-
nization of cytoskeleton which, particularly in neuro-
nal cells, is a major factor in controlling cellular
shape. In the nervous system, cellular shape is di-
rectly and intimately related to cellular function [24].
Our previous work has demonstrated that treat-
ment of transformed non-neuronal (CHO) cells ex-
pressing the human mt1 melatonin receptor with a
pharmacological concentration (1 WM) of melatonin
causes rapid cellular morphological changes consist-
ing of the formation of ¢lamentous structures that
strongly resemble neurites [25]. The morphological
changes noted were receptor-dependent and possibly
subtype-selective with the mt1 receptor being respon-
sible for the induced changes. We additionally re-
ported that the changes likely occur through inhibi-
tion of protein kinase A (PKA) inducing the
activation of MEK 1/2 and ERK 1/2 [25].
Previous work by Benitez-King and co-workers
[26] shows that N1E-115 mouse neuroblastoma cells
respond to melatonin exposure by forming neurites.
In their study, however, tests for the presence of
membrane-bound melatonin receptors were not con-
ducted. Based upon these results and those of other
studies [27^29], they interpreted their observations as
being due to the receptor-independent inhibition of
calmodulin function by direct melatonin binding. In
this study, we demonstrate the presence of speci¢c
high-a⁄nity melatonin receptors in N1E-115 cells
by 2-[125I]iodomelatonin binding studies. Western
blot analysis using an antibody speci¢c for the mt1
melatonin receptor con¢rms the presence of this re-
ceptor subtype.
2. Materials and methods
2.1. Cell culture
N1E-115 cells were the generous gift of Dr Mar-
shall Nirenberg (National Institutes of Health). Cells
were maintained in Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM) (Gibco-BRL, Gaithersburg, MD)
supplemented with 15% fetal bovine serum (Gibco-
BRL) and 1% penicillin/streptomycin (Gibco-BRL),
at 37‡C in a 5% CO2 atmosphere.
2.2. Treatment conditions
One day after passage of cells into 60-mm culture
dishes, they were treated as noted in Section 3. Mel-
atonin (Calbiochem, San Diego, CA) or N-[2-[2-(bro-
moacetoxy)-7-methoxynaphthyl]ethyl]propionamide
(BMNEP; [30]) solubilized in ethanol was added to
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achieve a ¢nal concentration of 1 nM. Treatments
were carried out for 24 h for the observation of cel-
lular shape changes and for 5 h for the analysis of
MEK/ERK pathway regulation. Pertussis toxin
(Sigma Chemical Co., St. Louis, MO) pretreatments
were carried out for 16 h at a concentration of 60 ng/
ml. The cells were subsequently treated with 1 nM
melatonin for 5 h. Control treatments consisted of
the addition of vehicle alone.
2.3. Radioligand binding assays
Samples of cellular membrane protein were pre-
pared by homogenizing suspended cells in 50 mM
Tris^HCl (pH 7.4) containing 1UComplete protease
inhibitors (Boehringer Mannheim). Following a low-
speed centrifugation to remove cellular debris
(500Ug, 10 min; 4‡C), the resulting supernatant
was centrifuged at 30 000Ug for 15 min at 4‡C.
Membrane pellets were resuspended in 50 mM
TRIS+protease inhibitors. For saturation analysis,
membrane fractions were added to tubes containing
50 mM TRIS and increasing concentrations of
2-[125I]iodomelatonin (1^800 pM) (DuPont NEN,
Boston, MA) in the absence (total binding) or pres-
ence (non-speci¢c binding) of 1 WM unlabeled mela-
tonin. Additional samples were incubated in the pres-
ence of 100 WM GTPQS (Sigma). Reactions were
incubated for 1 h at room temperature and then
¢ltered on glass ¢ber ¢lters (Daigger, Wheeling,
IL). Filter-bound radioactivity was determined with
a Packard Cobra II auto-gamma counter. Membrane
protein amounts were determined using the Bradford
protein assay (Bio-Rad, Hercules, CA). Binding data
are expressed as fmol of 2-[125I]iodomelatonin bound
per mg of membrane protein.
2.4. Western blotting
Membranes were prepared from N1E-115 cells cul-
tured as described above. Membrane samples were
also prepared from mt1-CHO, neo-CHO and MT2-
CHO cells [12,22] to provide a positive and two neg-
ative control samples, respectively. Total membrane
samples prepared from the cells harvested from two
150-mm diameter plates. Membrane pellets were
solubilized in Laemmli sample bu¡er [31], separated
with sodium dodecyl sulfate^polyacrylamide gel elec-
trophoresis (SDS^PAGE) and transferred to PVDF
membranes (Immobilon-P, Millipore, Bedford, MA).
Blots were probed with a rabbit polyclonal primary
antibody that recognizes the mt1 receptor (anti-hu-
man melatonin 1a receptor, CIDtech Research, On-
tario, Canada, 1:10 dilution). A donkey anti-rabbit
IgG secondary antibody conjugated with horseradish
peroxidase (1:2000 dilution) (Amersham Life Scien-
ces, Arlington Heights, IL), chemiluminescent detec-
tion (ECL-Plus, Amersham) and exposure to Kodak
BioMax Light ¢lm were used to visualize the protein
bands.
2.5. Cell counts and photography
Cell shapes were observed and scored for the pres-
ence of neurites using a Nikon TMS inverted micro-
scope equipped with phase-contrast optics. To quan-
tify the morphological changes in the cells induced
by melatonin treatment, populations of cells (100
cells/experimental group) were counted and classi¢ed
by shape. Cells were scored as to whether or not they
displayed neurite outgrowths. We speci¢cally carried
out these quanti¢cation experiments at subcon£uent
cell densities in order to avoid crowding-induced cell
shapes. Cell counts were made by an observer who
had no knowledge of the treatment that the cells had
received. Images were digitally captured using a
Scion Series 7 image capture system (Scion Corpora-
tion, Frederick, MD), minimally processed using
Adobe Photoshop software and printed with a Co-
donics NP-1660 Photographic Printer.
2.6. Statistical analysis
All data were analyzed by 1-way ANOVA fol-
lowed by the Newman^Keul’s post hoc test or a
two-tailed t-test (GraphPad Prism Software, Graph-
Pad Prism, San Diego, CA). Signi¢cance was de¢ned
as P6 0.05.
3. Results and discussion
3.1. N1E-115 cells produce neurites in response to
melatonin
The capability of N1E-115 cells to respond to mel-
BBAMCR 14711 5-1-01
S.L. Bordt et al. / Biochimica et Biophysica Acta 1499 (2001) 257^264 259
atonin was previously shown by Benitez-King and
co-workers [26]. In their studies, they found that
1 nM melatonin elicited a maximal response and
continued their treatments for up to 4 days. In our
studies, we treated N1E-115 cells with 1 nM melato-
nin or vehicle and noted a signi¢cant increase in
neurite formation by 24 h in melatonin-treated cells
(Fig. 1). For cells treated with vehicle, only
9.54 þ 0.04% of the cells produced neurites (Figs.
1A and 2) whereas in those cells treated with 1 nM
melatonin for 24 h 32.2 þ 0.92% (P6 0.05) produced
neurite outgrowths (Fig. 1B and 2). Although our
results con¢rm those of Benitez-King [26], it is im-
portant to note that the level of spontaneous neurite
production we observe (9.54%) is much lower than
that previously reported (V18%). We found that
incubation times longer than 24 h resulted in neurite
production at levels that obscured any melatonin ef-
fect (data not shown). It is known that N1E-115 cells
produce neurites in response to serum starvation [32].
In our studies, we included serum in the media at a
concentration of 15% instead of 10%. This higher
concentration of serum seemed to suppress sponta-
neous neurite production but did not eliminate it in
cells cultured for long periods. Additionally, we do
not believe that endogenous melatonin in the serum
(less than 10 pM) contributed to the spontaneous
production of neurites in N1E-115 cells as increases
in serum concentration served to suppress rather
than promote this kind of neurite formation.
3.2. 2-[125I]iodomelatonin binding con¢rms the
presence of melatonin receptors
Although Benitez-King and co-workers [26]
showed a melatonin-dependent formation of neurites
in N1E-115 cells, whether or not these e¡ects of mel-
atonin were mediated through speci¢c melatonin re-
ceptors was not assessed. Therefore our approach
was to use pharmacological and immunological anal-
yses to support or refute the presence of speci¢c mel-
atonin receptor subtypes. Saturation binding assays
performed with membrane preparations from N1E-
Fig. 2. Melatonin-induced outgrowth formation in N1E-115
cells. Graphical representation of the number of N1E-115 cells
displaying neurites following a 24-h exposure to vehicle, 1 nM
melatonin, 1 nM BMNEP or 1 nM melatonin following a 16-h
pretreatment with 60 ng/ml pertussis toxin. BMNEP fails to in-
duce neurite formation and pertussis toxin blocks the melatonin
e¡ect. Data represent the mean þ S.E.M. of three individual ex-
periments. aSigni¢cance from control (vehicle-treated) cells :
P6 0.05; bsigni¢cance from melatonin-treated cells : P6 0.05.
Fig. 1. Neurite production by N1E-115 cells after melatonin
treatment. (A) Cells treated with vehicle for 24 h show no neu-
rite outgrowths. (B) Cells treated with 1 nM melatonin for 24 h
show extensive neurite formation. Phase contrast micrographs.
Scale bar = 40 Wm.
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115 cells show saturable binding of 2-[125I]iodo-
melatonin. The binding maximum (Bmax) occurs at
a level of 3.43 þ 1.56 (n = 3) fmol/mg protein. The
Kd for half-maximal melatonin binding occurs at a
concentration of 240 pM (214^269 pM; n = 3). These
data are shown in Fig. 3A along with the data ob-
tained for binding in the presence of 100 WM GTPQS.
No melatonin binding is seen in the presence of
GTPQS, a typical response for a G-protein-coupled
receptor. The values obtained from the saturation
binding data are further supported through the
Scatchard analysis provided in Fig. 3B. These data
con¢rm the presence of high a⁄nity melatonin recep-
tors coupled to G-proteins. The values we observe
are well within the range of receptor binding re-
ported for native tissues [33]. For example, the
Bmax values we measure for N1E-115 cells are similar
to those obtained for hamster hypothalamus and
rabbit retina but are about 10-fold lower than that
for rabbit parietal cortex [33]. Similarly, the Kd value
for N1E-115 cells is close to that obtained for rabbit
retina but is higher than that for other native tissues
[33].
3.3. Western analysis demonstrates the presence of
mt1 receptors
Because our binding assays indicated that high af-
¢nity melatonin receptors were present in N1E-115
cells, we wanted to know which subtype(s) of recep-
tor exist in these cells. We probed Western blots of
membrane protein preparations with an antibody di-
rected against a peptide of the mt1 receptor subtype.
Fig. 4 shows that the mt1 subtype of melatonin re-
ceptors is present in N1E-115 cells. The molecular
mass of the band detected is approximately 37 kDa
and is in agreement with the previously reported size
for this receptor [34,35]. As a positive control, mem-
brane preparations of the transformed mt1-CHO cell
line [15,25] showed that the receptor subtype is
present in these cells as well. Negative control mem-
brane preparations from the transformed cell lines
MT2-CHO and neo-CHO, that produce the MT2
receptor subtype or no receptor, respectively, show
no signal. These results show for the ¢rst time that
the mt1 receptor subtype is present in N1E-115 cells.
It does not, however, eliminate the possibility of
MT2 subtype presence. No antibodies against the
MT2 receptor subtype are currently available.
Fig. 3. (A) Representative saturation binding of 2-[125I]iodo-
melatonin to N1E-115 cell membranes. Treatment of cells with
radiolabeled melatonin in the presence of 100 WM GTP-QS elim-
inated ligand binding. Bmax = 3.34 fmol/mg protein, Kd = 233
pM. (B) Representative Scatchard plot of the saturation iso-
therm. Bmax = 2.69 fmol/mg protein, Kd = 261 pM.
Fig. 4. Western blot showing the presence of mt1 receptors in
N1E-115 cell membranes. Membrane protein samples (100 Wg/
lane) were separated by SDS^PAGE and blotted onto PVDF
membranes. Blots were probed with a rabbit polyclonal anti-
body speci¢c for the mt1 receptor protein and detected with
chemiluminescence.
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3.4. An MT2 receptor-speci¢c agonist does not induce
neurites
In light of the lack of MT2 receptor-speci¢c
antibodies, we chose to test the e¡ects of the MT2
receptor-speci¢c activator BMNEP (N-[2-[2- (bromo-
acetoxy)-7-methoxynaphthyl] ethyl]-propionamide)
[30]. This compound has been shown to speci¢cally
alkylate and activate only MT2 receptors and is op-
timally e¡ective at a 1 nM concentration [30,36].
Treatment of cells with 1nM BMNEP for 24 h shows
a level of neurite formation (9.00 þ 0.29%) (Fig. 2)
that is the same as what is seen with vehicle treat-
ment alone (9.54 þ 0.04%) and is signi¢cantly lower
than what is noted for melatonin treatment alone
(32.2 þ 0.92%) (Fig. 2).
This result is in agreement with our previous ¢nd-
ings that MT2 receptor stimulation does not induce
neurite-like outgrowths in transformed non-neuronal
cells [25]. This indicates that the MT2 receptor sub-
type is most likely not a factor in bringing about the
cytoskeletal reorganizations needed for neurite out-
growth and suggests that MT2 receptors are prob-
ably not present in N1E-115 cells. We cannot, how-
ever, know this for certain until MT2 receptor
speci¢c antibodies are generated and/or lack of
gene expression is con¢rmed by other means.
3.5. Pertussis toxin eliminates melatonin-induced
neurite formation
It has been recently shown that the mt1 receptor
can carry out its signaling via three di¡erent G pro-
teins (GKi2, GKi3 and GKq=11) [19]. The Gi proteins are
pertussis toxin sensitive whereas the Gq proteins are
not. Therefore we wanted to determine the e¡ects of
pertussis toxin on melatonin-induced neurite forma-
tion in N1E-115 cells. Cells treated with 1 nM mel-
atonin following a 16 h pretreatment with 60 ng/ml
pertussis toxin show a reduced number neurites
formed (13.5 þ 0.56%) (Fig. 2). This value is not
statistically di¡erent from vehicle-treated cells
(9.54 þ 0.042) (Fig. 2). This result suggests that the
signals inducing neurite formation in these cells pro-
ceed through the pertussis toxin sensitive Gi path-
way. Given the fact that we demonstrate the presence
of the mt1 receptor subtype in these cells, the most
likely pertussis toxin sensitive mechanism of signal-
ing would be Gi2 and Gi3 protein mediated which
results in the inhibition of adenylyl cyclase activ-
ity[11]. This result is in agreement with our previous
¢ndings that suppression of protein kinase A (PKA)
activity, presumably due to the attenuation of ade-
nylyl cyclase activity, can lead to the production of
outgrowth structures in non-neuronal cells [25]. In
that work, we proposed that attenuation of PKA
activity leads to the activation of Raf-1 by reducing
its phosphorylation and thus allowing the MEK 1/2^
ERK 1/2 pathway to be activated. The induction of
neurite structures through an attenuation of cAMP
production is diametrically opposed to the ¢ndings in
cells such as PC12 [37], F11 [38], or NB2a [39] where
increases in cAMP result in neurite formation. This
apparent discrepancy is most likely to be resolved
through comparisons of receptor tyrosine kinase
stimulation vs. G-protein-coupled receptor stimula-
tion of di¡erentiation pathways.
Separate reports state that Gi proteins are capable
of interacting with the cytoskeleton [40,41]. An intact
cytoskeleton (microtubules and micro¢laments) may
alter the kinetics of Gi protein function and/or Gi
protein ribosylation may alter cytoskeletal turnover.
Treatment of N1E-115 cells with pertussis toxin re-
sults in the ADP-ribosylation of Gi proteins.
Whether or not this treatment a¡ects the cytoskeletal
dynamics in these cells is currently unknown. How-
ever, given the data presented in this and other stud-
ies [25], the possibility of pertussis toxin acting solely
through a mechanism separate from mt1 receptor
inactivation seems unlikely.
3.6. The MEK 1/2^ERK 1/2 pathway may be
constitutively stimulated in N1E-115 cells
Previous results from our laboratory and others
show that increases in the phosphorylated forms of
MEK 1/2 and ERK 1/2 are correlated with out-
growth formation in non-neuronal cells [25] and neu-
rite formation in neuronal cells [42^44]. Fig. 5 shows
the results of Western analysis of the two major com-
ponents of this pathway. We see elevated levels of
MEK 1/2 and ERK 1/2 phosphoproteins in N1E-115
cells; however, this increase is not melatonin depen-
dent. The levels of diphosphorylated ERK 1/2 are
particularly high and show no melatonin-dependent
changes. The high levels of the ERK 1/2 phospho-
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protein could indicate that the pathway is maximally
stimulated through a mechanism independent of mel-
atonin signaling. This level of presumably constitu-
tive ERK 1/2 activation could account for the high
level of spontaneous neurite production observed in
these cells. Several instances of constitutive Ras acti-
vation have been noted for carcinoma cells [45]. Be-
cause the N1E-115 cell line is derived from neuro-
blastoma tissue, it is possible that the Ras-mediated
branch of the MEK 1/2^ERK 1/2 pathway is consti-
tutively stimulated. This kind of stimulation could
lead to spontaneous neurite formation as though
the cells were being stimulated by a receptor tyrosine
kinase-linked neurotrophic factor.
In this work, we have shown that melatonin can
rapidly induce the formation of neurites in a central
nervous system-derived neuronal cell line and that
this induction most likely proceeds through high af-
¢nity melatonin receptors of the mt1 subtype. An
MT2 receptor-speci¢c agonist prevents neurite for-
mation in these cells and suggests that MT2 receptors
have no role in this process. These ¢ndings are in
agreement with our previous report that mt1 receptor
stimulation speci¢cally leads to cytoskeletal rear-
rangements in non-neuronal cells resulting in the for-
mation of neurite-like structures [25]. The possible
involvement of G-protein-coupled signaling in the
process of neurite formation could represent a novel
and alternative mechanism for neuronal di¡erentia-
tion separate from receptor tyrosine kinase induc-
tion. Neuronal induction, particularly within the cen-
tral nervous system where receptor tyrosine kinases
play a lesser role, could proceed instead via G-pro-
tein-coupled mechanisms and reveal new understand-
ings of neuronal development. Further investigations
of melatonin’s actions in neuronal di¡erentiation are
the focus of future investigations in our laboratories.
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